会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Ergoline derivatives
    • 二元醇衍生物
    • US4657914A
    • 1987-04-14
    • US488168
    • 1983-04-25
    • Luigi BernardiAldemio TemperilliSergio ManteganiGabriella TraquandiPatricia Salvati
    • Luigi BernardiAldemio TemperilliSergio ManteganiGabriella TraquandiPatricia Salvati
    • A61K31/48A61P9/12C07D457/02
    • C07D457/02
    • There are provided ergoline compounds of the formula: ##STR1## wherein R.sub.1 is a hydrogen atom or a methyl group; R.sub.2 is a hydrogen or halogen atom, a methyl or thiomethyl group; R.sub.3 is a hydrogen atom or a methoxy group; R.sub.4 is a hydrocarbon group having from 1 to 4 carbon atoms; n is 1 or 2; each of R.sub.5 and R.sub.6 independently is a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, or a phenyl or hydroxy or alkoxy group having from 1 to 4 carbon atoms, and X is an oxygen atom or a group of the formula NR.sub.7 wherein R.sub.7 is selected from the group consisting of a hydrogen atom, an alkyl having from 1 to 4 carbon atoms and a phenyl group, or a group of the formula N.dbd.C--R.sub.8 wherein the carbon atom is positioned between the nitrogen atoms in the ring and R.sub.8 is an amino, substituted amino, methyl, phenyl, thiomethyl or mercapto group. The compounds have antihypertensive and antiprolactin activity.
    • 提供下式的麦角灵化合物:其中R 1是氢原子或甲基; R2是氢或卤素原子,甲基或硫代甲基; R3是氢原子或甲氧基; R4是具有1至4个碳原子的烃基; n为1或2; R 5和R 6各自独立地为氢原子,具有1至3个碳原子的烷基或具有1至4个碳原子的苯基或羟基或烷氧基,X为氧原子或式 NR7,其中R7选自氢原子,具有1至4个碳原子的烷基和苯基,或式N = C-R8的基团,其中碳原子位于氮原子之间 环和R8是氨基,取代的氨基,甲基,苯基,硫代甲基或巯基。 该化合物具有抗高血压和抗催乳素活性。
    • 7. 发明授权
    • 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
    • 4,5,6,7-四氢咪唑并 - {8 4,5-c {9-吡啶衍生物
    • US4141899A
    • 1979-02-27
    • US838844
    • 1977-10-03
    • Giuliana ArcariLuigi BernardiGiovanni FalconiFulvio LuiniGiorgio PalamidessiUgo Scarponi
    • Giuliana ArcariLuigi BernardiGiovanni FalconiFulvio LuiniGiorgio PalamidessiUgo Scarponi
    • C07D471/04
    • Y10S514/926Y10S514/927
    • New 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine derivatives are disclosed, and more particularly derivatives of Formula I ##STR1## where R.sub.1 is hydrogen or an alkyl having from 1 to 4 carbon atoms;R.sub.2 is hydrogen, an alkyl having from 1 to 4 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, phenyl or a heterocycle;R.sub.3 is hydrogen, a saturated or unsaturated straight or branched alkyl having from 1 to 6 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, benzoyl or phenyl; andX is O, S or NR.sub.4 where R.sub.4 is hydrogen, an alkyl having from 1 to 4 carbon atoms, cyano, amino, nitro or acylamino;Or pharmaceutically acceptable acid addition salts thereof. Also disclosed is a process of preparing these compounds which comprises condensing an appropriate 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine with an appropriate alkyl isocyanate, alkyl isothiocyanate or substituted S-methyl thiourea, preferably in a solvent such as ethanol, acetonitrile or dioxane, usually under reflux for from 4 to 12 hours. The products can be isolated by crystallization as free bases or as salts of pharmaceutically acceptable acids. The new compounds have proved to be well tolerated and to inhibit both the number of experimental ulcers and the gastric secretion in experimental animals. Thus, they should prove useful in the therapy of gastric and duodenal ulcers in man.
    • 公开了新的4,5,6,7-四氢咪唑并[4,5-c] - 吡啶衍生物,更具体地,其中R 1是氢或具有1至4个碳原子的烷基的式I的衍生物; R 2是氢,具有1至4个碳原子的烷基,具有3至6个碳原子的环烷基,苯基或杂环; R3是氢,具有1至6个碳原子的饱和或不饱和直链或支链烷基,具有3至6个碳原子的环烷基,苯甲酰基或苯基; 且X为O,S或NR 4,其中R 4为氢,具有1至4个碳原子的烷基,氰基,氨基,硝基或酰氨基; 或其药学上可接受的酸添加剂。 还公开了制备这些化合物的方法,其包括将合适的4,5,6,7-四氢咪唑并[4,5-c] - 吡啶与适当的烷基异氰酸酯,异硫氰酸烷基酯或取代的S-甲基硫脲缩合,优选在 溶剂如乙醇,乙腈或二恶烷,通常在回流下4至12小时。 可以通过结晶作为游离碱或药学上可接受的酸的盐分离产物。 这些新化合物已被证明是良好的耐受性,并且在实验动物中抑制实验性溃疡的数量和胃分泌。 因此,它们应该证明在治疗人和十二指肠溃疡方面是有用的。